Belite Bio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Belite Bio wird ein Gewinn- und Umsatzwachstum von 60.6% bzw. 66% pro Jahr prognostiziert, während der Gewinn pro Aktie um 59.5% pro Jahr wachsen soll.

Wichtige Informationen

60.6%

Wachstumsrate der Gewinne

59.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.5%
Wachstumsrate der Einnahmen	66.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

Jul 03

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Mar 20

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Jan 10

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

Jul 31

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

May 03

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct 03

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Jul 19

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BLTE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	32	-19	-10	N/A	3
12/31/2025	10	-26	-30	N/A	5
12/31/2024	N/A	-31	N/A	N/A	5
3/31/2024	N/A	-33	N/A	N/A	N/A
12/31/2023	N/A	-32	-30	-30	N/A
9/30/2023	N/A	-31	N/A	N/A	N/A
6/30/2023	N/A	-23	N/A	N/A	N/A
3/31/2023	N/A	-18	N/A	N/A	N/A
12/31/2022	N/A	-13	-12	-11	N/A
9/30/2022	N/A	-8	N/A	N/A	N/A
6/30/2022	N/A	-8	N/A	N/A	N/A
3/31/2022	N/A	-8	N/A	N/A	N/A
12/31/2021	N/A	-10	-8	-7	N/A
9/30/2021	N/A	-9	N/A	N/A	N/A
6/30/2021	N/A	-8	-7	-7	N/A
3/31/2021	N/A	-7	-6	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BLTE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BLTE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BLTE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: BLTEDie Einnahmen des Unternehmens (66% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: BLTEDie Einnahmen des Unternehmens (66% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BLTE in 3 Jahren voraussichtlich hoch sein wird

Belite Bio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 21% to US$45.67

Recent updates

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

CFO & Director notifies of intention to sell stock

Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Belite Bio, Inc has filed a Follow-on Equity Offering in the amount of $24.999964 million.

Director notifies of intention to sell stock

Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Chief Scientific Officer notifies of intention to sell stock

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

CFO & Director notifies of intention to sell stock

Director notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

New minor risk - Shareholder dilution

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

New major risk - Share price stability

Price target decreased by 21% to US$45.67

Belite Bio, Inc. Doses First Subject in Pivotal Phase 3 Phoenix Trial Evaluating Oral Tinlarebant for Ga

Belite Bio, Inc. Completes Enrollment in Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant for Stargardt Disease

Belite Bio, Inc to Report Q1, 2023 Results on May 10, 2023

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Belite Bio, Inc Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

Less than half of directors are independent

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Belite Bio, Inc Presents 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease At AAO Annual Meeting 2022

Belite Bio Receives Approval of Lbs-008 Phase 3 Clinical Trial in China

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of Lbs-008 in Stargardt Disease in the U.S

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

Belite Bio GAAP EPS of -$0.23 beats by $0.05

Belite Bio, Inc to Report Q2, 2022 Results on Aug 10, 2022

Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Belite Bio, Inc Submits Investigational New Drug Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Belite Bio, Inc Presents Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

Belite Bio Receives FDA Fast Track Designation For LBS-008

No independent directors

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken